Related Experiment Videos
[Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model]
1Department of Nervous System Pathology, Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Baltiiskaya ul. 8, Moscow, 125315 Russia.
Abstract:
Preliminary peroral administration of mexidol into mice with (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced parkinsonism model prevented the formation of malonaldehyde in striatum. In combination with small doses of L-DOPA (2-mg/kg), mexidol decreased oligokinesia and muscular rigidity manifestations and increased the levels of dopamine and its metabolites--dioxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in striatum. The combined (mexidol + L-DOPA) drug administration produced a 3-5 h increase in the time of the parkinsonism syndrome inhibition as compared to that upon the administration of a greater L-DOPA dose (100 mg/kg) without mexidol. It is suggested that mexidol, possessing antioxidant properties, is capable of preventing the damage and loss of the nigrostriatial dopaminergic neurons.
Insights
Mexidol, an antioxidant, protected against neurodegeneration in a Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Parkinsonism is a neurodegenerative disorder characterized by motor symptoms.
- Oxidative stress and dopaminergic neuron loss are key pathological features.
- Current treatments like L-DOPA have limitations and side effects.
Purpose of the Study:
- To investigate the neuroprotective effects of Mexidol in a Parkinson's disease model.
- To evaluate the combined efficacy of Mexidol and L-DOPA in mitigating Parkinsonism symptoms.
Main Methods:
- Induction of Parkinsonism in mice using (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
- Administration of Mexidol alone and in combination with varying doses of L-DOPA.
- Measurement of malonaldehyde, dopamine, DOPAC, and HVA levels in the striatum.
- Assessment of motor functions like oligokinesia and muscular rigidity.
Main Results:
- Mexidol prevented malonaldehyde formation, indicating reduced oxidative stress.
- Combined Mexidol and low-dose L-DOPA (2 mg/kg) improved motor symptoms and dopamine levels.
- The combination therapy prolonged symptom inhibition by 3-5 hours compared to high-dose L-DOPA alone (100 mg/kg).
Conclusions:
- Mexidol exhibits antioxidant properties beneficial in a Parkinson's model.
- Combining Mexidol with L-DOPA enhances therapeutic efficacy and duration.
- Mexidol may protect nigrostriatal dopaminergic neurons from damage and loss.